Subcutaneous Testosterone Implants
DrugSubcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism
NCT Number: NCT07500766
Introduction:
Male hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil.
Objective:
To evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism.
Methods:
This is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction.
Outcomes:
The primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng/dL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence.
Clinical Significance:
This study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction.
Relevance and Impact:
This is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).
Trial opening soon.
Get Notified18 year and older
Male
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism
Time frame: 180 days
To evaluate the efficacy of a resorbable subcutaneous testosterone implant (200 mg), administered at a total dose of 800 mg (four 200-mg implants), in achieving and maintaining total serum testosterone concentration between 450 and 800 ng/dL in symptomatic hypogonadal men over a 180-day period
Time frame: Up to 180 days
Assessment of the maximum plasma concentration of total testosterone.
Time frame: Up to 180 days
Assessment of the time required to reach the maximum plasma concentration of total testosterone after implantation.
Time frame: Up to 180 days
Assessment of the elimination half-life of total testosterone in plasma following implantation.
Time frame: Up to 180 days
Assessment of the average plasma concentration of total testosterone following implantation.
Time frame: Up to 180 days
Assessment of the area under the curve of plasma concentration.
Time frame: 180 days
Evaluate the incidence of complications in a clavien dindo scale
Time frame: Up to 180 days
Assessment of changes in serum luteinizing hormone (LH) levels during treatment with testosterone implants.
Time frame: 180 days
To evaluate the incidence of erectile dysfunction withe the International Index of Erectile Function.
Time frame: 180 days
Evaluate the plasma thromboelastography in men treated with testosterone implants.
Time frame: Up to 180 days
Assessment of changes in hypogonadal symptoms using the Androgen Deficiency in the Aging Male questionnaire.
Time frame: 180 days
To evaluate changes in quality of life in hypogonadal patients undergoing testosterone replacement therapy with implants with the World Health Organization Quality of Life - BREF (WHOQOL-BREF) assessment questionnaire score.
Time frame: 180 days
To evaluate the metabolic effects of testosterone implants on the serum lipid profile
Time frame: 180 days
To assess patient satisfaction with a numerical Likert scale 1 to 5
Time frame: 180 days
To compare patient satisfaction with testosterone implants versus other testosterone replacement therapy modalities previously used by the participants, with a qualitative comprehensive questionnaire and a numerical final grade from 1 to 100
Time frame: Up to 180 days
Assessment of changes in serum follicle-stimulating hormone (FSH) levels during treatment with testosterone implants.
Time frame: Up to 180 days
Assessment of changes in serum prostate-specific antigen (PSA) levels during treatment with testosterone implants.
Time frame: 180 days
Evaluate the incidence of regret in the use of testosterone implant treatment in a 1-5 Likert scale.
Time frame: 180 days
To evaluate the metabolic effects of testosterone implants on body mass index in kg/m2 (BMI)
Time frame: 180 days
To evaluate the metabolic effects of testosterone implants on the measure of waist circumference in centimeters (cm).
Contact information is provided by the study sponsor or research team.
University of Sao Paulo
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07476222
Androgen Deficiency, Atrophy
Andijan, Uzbekistan
View Trial DetailsNCT00858650
Androgen Deficiency, Endocrine System Diseases
Halle, Germany
View Trial DetailsNCT03721497
Atrophy, Bariatric Surgery Candidate
Esbjerg, Denmark
View Trial DetailsNCT01699178
Endocrine System Diseases, Eunuchism
Birmingham, Alabama, United States
View Trial Details